A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults

September 25, 2018
https://clinicaltrials.gov/ct2/show/NCT03547908
Infectious Disease
Principal Investigator: Indira Brar, MD
Bictegravir/Emtricitabine/Tenofovir Alafenamide, Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate, Treatment Naïve, HIV-1, Hepatitis B
Accepting Participants